🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Don’t miss the OncoAlert🚨newsletter #ASCO25 EDITION⭐️ REGISTER👉OncoAlert360.com OR buff.ly/48Xpgz0 Matteo Lambertini, MD PhD Petros Grivas Daniel Castellano Tom Powles Uromigos Janice Cowden Simon C Axel S. Merseburger Icro Meattini Erika Hamilton, MD Sara Tolaney MEDSIR

Petros Grivas (Petros Grivas), Joan Schiller of Oncology Advocates United for Climate and Health, Zachary Avigan (Zach Avigan, MD) receive ECOG-ACRIN (ECOG-ACRIN Cancer Research Group) 2025 scientific leadership, mentorship awards cancerletter.com/in-brief/20250…

Just in Clinical Cancer Research 👉Congrats Chadi Hage Chehade Umang Swami & GU Cancer Research Program @HuntsmanCancer team👉Poor outcomes w/ SOC Rx in mHSPC #prostatecancer w/HRRm in 637 real-world US pts👇 Flatiron Health Foundation Medicine Ryon Graf, PhD 👉 need to add PARPi 👉free link: bit.ly/3TsOw9i OncoAlert UroToday.com

Excited to see our work published in Clinical Cancer Research ! Real-world pts w/ mHSPC #prostatecancer w/ HRRalt had worse survival than those w/ non-altered HRR 👉bit.ly/3TsOw9i👇 Grateful for terrific support from team Ryon Graf, PhD Umang Swami Neeraj Agarwal, MD, FASCO UroToday.com OncoAlert

Best of ASCO in Seattle - Petros Grivas Petros Grivas Binaytara ASCO oncodaily.com/opinion/petros… #OncoDaily #Oncology #Cancer #Health #Medicine #MedX #MedEd #MedNews CancerWorld

Convalescent Plasma and Survival in Hematologic Malignancy and COVID-19 [Jun 17, 2021] Mike Thompson, MD, PhD, FASCO & Jeff Henderson MDPhD et al. Jack Senefeld Dimpy Shah MD, PhD @hemoncwarner COVID-19 and Cancer Consortium (CCC19) Registry - JAMA Oncology ow.ly/SJJu50FcCmD #COVID19CP #CCC19 #COVID19nCancer #COVID19 #IDonc

Association of Clinical Factors & Recent Anti-Cancer Therapy with COVID-19 Severity among Patients with Cancer: A Report from the COVID-19 and Cancer Consortium [3/18/21] Petros Grivas Ali Khaki et al. COVID-19 and Cancer Consortium (CCC19) Registry Annals of Oncology ow.ly/RSt450E2I9U #CCC19 #COVID19nCancer

Big news from nature 🔍 Transparent peer review is now standard for all research papers. Referee reports + author replies will be published with each article. More clarity. More trust. More accountability. How do you think this will affect science? #Science #PeerReview

Join us in Athens June 26-28 for fantastic oncology meeting with stellar experts! Great for trainees :-) Shilpa Gupta Nick James also on @Prof-Nick-James.bsky.social Karima Oualla, MD,MSc Maite Bourlon Vivek Subbiah, MD Manmeet Ahluwalia, MD, MBA, FASCO Stephanie Berg @WHBA1990 MikaLion Marinos Tsiatas ANASTASIOS KYRIAZOGLOU facebook.com/share/v/1BqHiA…

Petros Grivas Binaytara ASCO Fred Hutch Cancer Center Nicole D. Fleming MD Binay Shah, MD, MHA Chirag Shah Vyshak Venur, MD Lisa Tachiki, MD Danai Dima Ronan Hsieh, MD, MS Mazyar Shadman, MD MPH Hsieh Lab Lei Deng, MD (He/Him) We would like to inform you that your post has been published on OncoDaily.com. Thank you for sharing. oncodaily.com/opinion/petros…

The number of female #BreastCancer survivors is projected to reach 5.3 million by 2035—an increase of one million women from 2025, marking the largest projected growth among the top 10 most prevalent cancers. More stats at: 🔗 acsjournals.onlinelibrary.wiley.com/doi/full/10.33… OncoAlert Nikita Wagle, PhD, MBBS, MHA

📢 Big win for a rare kidney cancer subtype! In HLRCC-associated papillary RCC, bevacizumab + erlotinib delivered a 72% response rate and median PFS of 21.1 months. 🧬 Germline FH-mutated pRCC finally gets a targeted shot. #Oncology #RCC #HLRCC #KidneyCancer #PrecisionMedicine

⚡️ NMIBC follow-up: what does the EAU recommend? - Tailored schedule by risk level - CT urography for high-risk patients - No approved biomarker can replace cystoscopy - BLFC & NBI help detect missed lesions #BladderCancer European Association of Urology (EAU) uroweb.org/guidelines/non…

Out in NEJM!! 🚨 Breakthrough in HLRCC-associated RCC! A Phase 2 trial shows that 💉bevacizumab + erlotinib offers high efficacy in advanced papillary renal cell carcinoma: 🔬 HLRCC-associated pRCC: ✅ 72% response rate ⏱️ Median PFS: 21.1 mo 💀 Median OS: 44.6+ mo 🔬 Sporadic

Last chance to register FREE for #IUCS25 in Portsmouth or online! Join leading experts in urology cancer on Sept 4-5 for cutting-edge science & networking. Submit your abstract by June 30 for poster & mini-oral! 🔗 Register & submit: urologycancersummit.org #Urology OncoAlert

Squamous cell carcinoma of unknown primary (SCCUP): a genomic landscape study in ESMO Open. High frequency of biomarkers associated with response to immunotherapy, as well as other potentially targetable biomarkers. esmoopen.com/article/S2059-…

Thank you Cancer Today AACR for featuring our recent ESMO - Eur. Oncology Real World Data & Digital Oncology study on the portrayal of cancer in public figures in news stories. The public should be cognizant that many news articles lack pertinent details on an individual's diagnosis,

🔬 CONTACT-02 Phase 3 Trial in mCRPC 🔬 📍 Patients with metastatic castration-resistant prostate cancer + extrapelvic soft-tissue mets post-ARPI 💊 Cabozantinib + Atezolizumab vs ARPI switch ✅ PFS: 6.3 vs 4.2 mo (HR 0.65, P=0.0007) ❌ OS: No significant difference (14.8 vs

An excellent review on optimising treatment of stage 2 seminoma. Very well written highlighting the double edge sword - efficacy and toxicity. doi.org/10.1200/OP-25-… Toni Choueiri, MD UroToday.com Jonathan Rosenberg MD Bradley McGregor Karine Tawagi MD Rana McKay, MD, FASCO Matt Galsky Bhardwaj Lab

Fantastic to work with great leader, visionary, charismatic, committed to patient care, research, education, growth, outreach, innovation! Thanks Dr. Tom Lynch Fred Hutch Cancer Center for all your work! Nicole D. Fleming MD Mazyar Shadman, MD MPH Julie Gralow Lynn Schuchter Margaret Foti, PhD, MD (hc) Vivek Subbiah, MD Ishwaria Subbiah, MD MS FASCO